BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-07-30
Last Posted Date
2022-03-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
102
Registration Number
NCT04493567
Locations
🇺🇸

ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States

🇺🇸

Anaheim Clinical Trials, Anaheim, California, United States

Participant Reported Outcomes and Treatment Experiences in Kidney Cancer

Completed
Conditions
First Posted Date
2020-07-15
Last Posted Date
2022-04-26
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
5
Registration Number
NCT04472663
Locations
🇺🇸

Local Institution, Morristown, New Jersey, United States

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2020-07-15
Last Posted Date
2022-10-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
61
Registration Number
NCT04472494
Locations
🇺🇸

Atlantic Health System, Morristown, New Jersey, United States

🇵🇷

CardioPulmonary Research, Guaynabo, Puerto Rico

🇵🇷

Ponce Medical School Foundation, Ponce, Puerto Rico

and more 7 locations

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-07-14
Last Posted Date
2022-01-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
35
Registration Number
NCT04470778
Locations
🇺🇸

ICON (PRA Health Sciences) - Salt Lake, Salt Lake City, Utah, United States

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

First Posted Date
2020-07-13
Last Posted Date
2022-05-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
24
Registration Number
NCT04468815
Locations
🇺🇸

ICON (LPRA) - Salt Lake, Salt Lake City, Utah, United States

A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235

First Posted Date
2020-07-09
Last Posted Date
2022-03-25
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT04464577
Locations
🇺🇸

Local Institution, Salt Lake City, Utah, United States

Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants

First Posted Date
2020-06-23
Last Posted Date
2022-10-20
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
48
Registration Number
NCT04444050
Locations
🇺🇸

Local Institution - 0001, Anaheim, California, United States

🇺🇸

ICON (LPRA) - Lenexa, Lenexa, Kansas, United States

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

First Posted Date
2020-04-16
Last Posted Date
2024-07-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
112
Registration Number
NCT04349072
Locations
🇺🇸

Local Institution, Houston, Texas, United States

🇺🇸

Local Institution - 0015, Rochester, Minnesota, United States

🇺🇸

Local Institution - 0002, Portland, Oregon, United States

and more 18 locations

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

First Posted Date
2020-04-16
Last Posted Date
2024-10-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
44
Registration Number
NCT04349267
Locations
🇺🇸

Local Institution - 0001, Germantown, Tennessee, United States

🇺🇸

Local Institution - 0028, Sioux Falls, South Dakota, United States

🇨🇦

Local Institution - 0013, Ottawa, Canada

and more 5 locations

A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

First Posted Date
2020-04-09
Last Posted Date
2024-11-26
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
26
Registration Number
NCT04340193
Locations
🇺🇸

Local Institution - 0059, Louisville, Kentucky, United States

🇸🇬

Local Institution - 0027, Singapore, Singapore

🇺🇸

Local Institution - 0189, Coronado, California, United States

and more 86 locations
© Copyright 2024. All Rights Reserved by MedPath